Latest news with #ChronicObstructivePulmonaryDisease
New Indian Express
6 hours ago
- Health
- New Indian Express
All PHCs in Tiruchy to start COPD screening from June 4
TIRUCHY: From June 4, all 84 primary health centres (PHCs) in the district, including those under the corporation, will launch structured screening for Chronic Obstructive Pulmonary Disease (COPD), a progressive lung condition often under-diagnosed in its early stages. The initiative, which is part of the COPD control programme announced recently in the state Assembly by Health Minister Ma Subramanian, aims to enable early identification of cases and ensure timely referral to specialists. It is also part of efforts, to maintain through the PHCs, a digital registry integrated with the Makkalai Thedi Maruthuvam (MTM) portal, supporting both long-term treatment and preparedness during respiratory outbreaks. Under the new programme, adults above 35 years presenting with symptoms such as chronic cough (lasting more than eight weeks), sputum production and breathlessness, and particularly with a history of smoking, indoor biomass fuel use and dust-heavy occupations, will be screened for COPD at PHCs. If needed, they will be referred to the Mahatma Gandhi Memorial Government Hospital (MGMGH).
Hans India
a day ago
- Health
- Hans India
Tobacco use claims 1.35 million lives annually
Berhampur: There are more than 1.35 million deaths due to tobacco use in India and 8.7 million deaths in the world every year. This was stated by eminent chest physician Narayan Mishra during a rally organised for the youth at MKCG Medical College Play Ground here on Tuesday. 'Tobacco use can affect any organ of the body. Inhalation from tobacco affects mostly respiratory systems causing Chronic Obstructive Pulmonary Disease (COPD), lung cancer, hypertension and coronary artery disease. Mouth cancer is linked to chewing tobacco. The addiction problem can be tackled with the help of specialised doctors and de-addiction centres', said Mishra. The rally was organised by Rotary District 3262 in association with IMA, NCCP, ICS and Physical Academy of Berhampur on the occasion of 'World No Tobacco Day'. The theme for the year 2025 is 'Bright Product. Dark intentions.' It highlights the hidden dangers of tobacco products that come in appealing flavours and packing. The rally was attended by more than 600 youngsters. Chief Guest Past District Governor of Rotary International Jayashree Mohanty inaugurated the programme and flagged off the rally.
Yahoo
3 days ago
- Business
- Yahoo
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD). While one trial met its primary endpoint, the other missed, raising concerns about the drug's future and delaying its potential market entry. This setback, likely spooked investors and contributed to the significant decline. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it's free. Regeneron's shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for Regeneron and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was about 1 month ago when the stock dropped 9.6% on the news that the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales. Overall, this quarter could have been better. Regeneron is down 31.8% since the beginning of the year, and at $487.82 per share, it is trading 59.4% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of Regeneron's shares 5 years ago would now be looking at an investment worth $813.74. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
The Hindu
3 days ago
- Health
- The Hindu
The cheapest way to prevent NCDs: reducing salt consumption
According to the World Health Organization (WHO), more than 70% of deaths in low- and middle-income group countries are due to non-communicable diseases (NCDs). Poor lifestyles, smoking, the use of alcohol, lack of exercise, air pollution, and other factors contribute to this figure. It is of paramount importance to prevent NCDs, as their treatment can be a huge burden to the health budget of a country. One of the easiest and most cost-effective ways of preventing NCDs is reducing salt consumption in the population. Salt consumption, the WHO says, should be less than 5 grams per day from all sources: this includes natural sources, salt added while cooking, and hidden salt in processed and packaged food. Indians consume way above the recommendation at around 8 to 11 grams per day. It is important to clarify the confusion between sodium and salt. Two grams of sodium is equal to 5 grams of common salt. The relationship between salt and blood pressure is well known. High salt intake leads to increased blood volume, and unless the endothelium (lining of the blood vessels) produces nitrous oxide, the blood vessel fails to dilate, leading to hypertension. This is called salt-sensitive or resistant hypertension and is genetically determined. However, what is not common knowledge is that salt-resistant hypertension can become salt-sensitive over time. High salt in the absence of hypertension can also lead to endothelial dysfunction. All NCDs have a common pathology of blood vessel damage. The ill effects of hypertension: contributing to heart attacks, strokes, and kidney failure are well known. And so, it is essential that salt intake is followed to the recommended level even in the absence of hypertension. What the research says There are more than 100 studies that have shown the benefit of salt reduction in the population. Studies from Japan, Portugal, and Finland are the oldest. A study from the U.K. showed a reduction of strokes by 24% and heart attacks by 18% when salt intake was reduced. The latest and the largest study from China, showed a considerable reduction in strokes with the use of low-sodium salt substitutes. The other ill effects of salt, such as kidney stones, worsening of Chronic Obstructive Pulmonary Disease (COPD), stomach cancer, and osteoporosis, must be included in the benefits of salt control. How to control salt consumption The first step is creating awareness at all levels of the general population, health providers, the government, and food manufacturers. The best way to find out daily salt consumption is by estimating urine sodium over 24 hours. In general, the salt we eat is removed from our urine. Only a very small quantity is lost in faeces or sweat. It is a common misconception that with increased sweating, the body requires more salt: only more water is required. Unfortunately, only about 3,000-odd people have been studied for urinary sodium excretion, which is miniscule considering our population. Studies using dietary recall are not reliable, however, knowing the average family consumption may help to monitor and advise accordingly. Salt meters have been used in some countries but do not help in determining salt in traditional Indian foods. Studies from our country still show that the majority of salt is added while cooking at home. But this is likely to change, since eating out and consumption of packaged food have been on the rise. The average person cooking at home needs to be educated on the skill of lowering salt through the use of spices and condiments to improve taste. More salt is not required to improve taste. On the contrary, salt is a dominant taste and masks other flavours. The saltshaker need not be displayed on the table, since it is often used without tasting the food. Taste is often an acquired habit, and desensitisation may help with this. Eating out is another source of salt intake with poor control. This has increased with families becoming small, and where both or all adults are working. The Sapiens Health Foundation in Chennai, which has been campaigning for low salt intake for the past 15 years, has successfully persuaded several restaurants to not display saltshakers on the table. The public procurement of food is also an area where salt can be controlled. Midday meals at schools should be an important target. The benefit of this can be immense since the habit is inculcated from childhood. The United Kingdom, for instance, has a very strong policy where meals in schools are served without salt. There is also a lack of awareness about how much salt children require. It is only by the age of 12 that they must reach the recommended intake of 5 grams per day. The transport sector is an important site of public procurement of food. For instance, travellers buy fresh food from stalls at railway stations. Unfortunately, a majority of the airlines serve packed food. These are areas that need to be looked into. The need for food labelling The government plays a very important role in controlling the salt intake of the population. Here, food labelling is crucial: labels for sodium should be made mandatory. Labels need to be on the front of the package and need to be clear and legible. Food labels should be marked for high salt content since the common man may not be able to interpret the sodium content. Signal labelling, using red to indicate high salt has been used successfully in the UK. The government can also increase taxes for high-salt items just as it has for cigarettes. Creating awareness in the population is another step and should be taken up by the Ministry of Information and Broadcasting. The Food Safety and Standards Authority of India has initiated the 'Eat Right India' movement which is a collaborative effort with multiple sectors. These, and more, are needed to build awareness around reducing salt consumption. The food industry has to gear up to reformulate food items. Low-salt alternatives for popular brand snacks should be freely available. We should take a leaf out of the UK's book where, for 10 years, the salt content in bread was reduced slowly and progressively without most people realising it. The acceptance was widespread. Lastly, salt substitutes, although available in India, are not popular. They have varying levels of sodium being replaced by potassium. Normally, in up to 20% of this replacement, there is no difference in taste. The only concern with this is in people with kidney impairments, as it may produce hyperkalemia or high serum potassium. The WHO has recently released guidelines on the use of low-sodium salt substitutes. Low sodium salt substitutes should not be confused with other sodium salts in the market such as rock salt or pink salt, which still contain high sodium and have no benefits; on the contrary, they are non-iodised and might lead to iodine deficiency. Salt targets must be set every three years so that ultimately, we achieve the WHO goal of 5 grams per day. The large-scale implementation of a campaign to reduce salt/sodium intake among the population remains the best and most cost-effective way to reduce strokes, heart attacks, kidney failure, and other NCDs. (Dr. Rajan Ravichandran is director, MIOT Institute of Nephrology, Chennai, and founder, Sapiens Foundation.)
Yahoo
19-05-2025
- Health
- Yahoo
Chronic Obstructive Pulmonary Disease (COPD) Seven-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033
Explore the future of the Chronic Obstructive Pulmonary Disease (COPD) market with our comprehensive report. This forecast model covers the 7 major markets from 2023 to 2033, predicting a CAGR of 10%, growing from $11.6 billion in 2023 to $30.2 billion by 2033. Discover market insights, pipeline analysis, and strategies for effective competitiveness in the 7MM COPD therapeutics landscape. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Chronic Obstructive Pulmonary Disease (COPD): Seven-Market Drug Forecast and Market Analysis - Update (2025)" has been added to offering. This comprehensive report provides an in-depth analysis of the Chronic Obstructive Pulmonary Disease (COPD) market across seven major markets, featuring an Excel-based model forecasting market trends through 2033. COPD, a progressive lung disease, continues to present significant health challenges globally. Our analysis investigates this market's path over the next decade, beginning with an estimated value of $11.6 billion in 2023 and projecting growth to $30.2 billion by 2033, reflecting a compound annual growth rate (CAGR) of 10.0%. Our forecast encompasses both currently marketed and pipeline drugs tailored for COPD, with 2023 as the base year. Key deliverables include a detailed PDF report along with an Excel-based model providing intricate market forecasts. Key Highlights Forecasting tools offered include a PDF report and an Excel-based model. The 7MM serves as the focal point for our projections spanning 2023 to 2033. Scope Provides a detailed overview of COPD, addressing epidemiology, symptoms, diagnosis, disease management, and the Asthma-COPD Overlap (ACO). Includes annualized market revenue data, per patient therapy costs, and treatment usage forecasts for the period 2023-2033. Covers strategic competitor assessments, market dynamics, unmet needs, clinical trials, and their collective impacts on COPD therapeutics. Features pipeline analysis, presenting data on emerging therapeutic trends and development mechanisms, highlighting promising late-stage candidates. Presents a competitive analysis of the global COPD market, exploring industry drivers, barriers, and challenges. Key Topics Covered: Chronic Obstructive Pulmonary Disease: Executive Summary Introduction Disease Overview Epidemiology Disease Management Current Treatment Options Unmet Needs and Opportunity Assessment R&D Strategies Pipeline Assessment Pipeline Valuation Analysis Current and Future Players Market Outlook Appendix About the Analyst Contact the Publisher Companies Featured Sanofi Regeneron GSK AstraZeneca Verona Pharma Chiesi Pharma Roche Genentech Boehringer Ingelheim Theravance Biopharma Novartis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
